The use and development of retroviral vectors to deliver cytokine genes for cancer therapy

Critical Reviews in Therapeutic Drug Carrier Systems

Volumn 17, Issue 1, 2000, Pages 1-60

  Fong, Timothy C ^a   Sauter, Sybille L ^b   Ibañez, Carlos E ^b   Sheridan, Philip L ^b   Jolly, Douglas J ^b  

^a RPR Gencell   (United States)

^b NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Cancer; Cytokine; Intratumoral; Retroviral vector

Indexed keywords

VIRUS VECTOR;

CANCER THERAPY; DRUG DESIGN; DRUG MANUFACTURE; DRUG QUALITY; GENE TARGETING; GENE THERAPY; RETROVIRUS; REVIEW;

EID: 0034062676     PISSN: 07434863     EISSN: None     Source Type: Journal    
DOI: 10.1615/critrevtherdrugcarriersyst.v17.i1.10     Document Type: Review

References (267)

1. Ellermann, V. and Bang, O., Experimentelle Leukaemie bei Huehnern, Zentralbl. Bakteriol. Parasitenkd. Infectionkr. Hyg. Abt. Orig., 46, 595, 1908.
2. Rous, P., A sarcoma of the fowl transmissible by an agent separable from the tumor cells, J. Exper. Med., 13, 397, 1911.
3. Loewer, R., Loewer, J., and Kurth, R., The viruses in all of us: Characteristics and biological significance of human endogenous retrovirus sequences, Proc. Natl. Acad. Sci. USA, 93, 5177, 1996.
4. Villareal, L. P., On viruses, sex, and motherhood, J. Virol., 71, 859, 1997.
5. Wilkinson, D. A., Goodchild, N. L., Saxton, T. M., Wood, S., and Mager, D. L., Evidence for a functional subclass of the RTVL-H family of human endogenous retrovirus-like sequences, J. Virol., 67, 2981, 1993.
6. Coffin, J. M., Hughes, S. H., and Varmus, H. E., Retroviruses, Cold Spring Harbor, NY: Cold Spring Harbor Laboratory, 1997.
7. Coffin, J. M., Retroviridæ: The viruses and their replication, in Virology, 3rd ed., Fields, B. N., Knipe, D. M., Eds., New York, NY: Raven Press, 1767, 1996.
8. Jolly, D., Viral vector systems for gene therapy, Cancer Gene Ther., 1, 51, 1994.
9. Anon, Human gene marker/therapy clinical protocols, Hum. Gene Ther., 9, 935, 1998.
10. Purcell, D. F., Broscius, C. M., Vanin, E. F., Buckler, C. E., Nienhuis, A. W., and Martin, M. A., An array of murine leukemia virus-related elements is transmitted and expressed in a primate recipient of retroviral gene transfer, J. Virol., 70, 887, 1996.
11. Onodera, M., Nelson, D. M., Sakiyama, Y., Candotti, F., and Blaese, R. M., Gene therapy for severe combined immunodeficiency caused by adenosine deaminase deficiency: Improved retroviral vectors for clinical trials, Acta Hematol., 101, 89, 1999.
12. Robbins, P. D. and Ghivizzani, S. C., Viral vectors for gene therapy, Pharmacol. Ther., 80, 35, 1998.
13. + progenitor cells using retroviral vectors produced by a canine packaging cell line, Biol. Blood Marrow Transplant, 4, 119, 1998.
14. Todd, S., Anderson, C-G., Jolly, D.J., and Craik, C. S., HIV protease as a target for retrovirus - Mediated gene therapy, Biochim. Biophyis. Acta, in press.
15. Nemuniatis, J., Fong, T., Burrows, F., Bruce, J., Peters, G., Ognoskie, N., Meyer, W., Wynne, D., Kerr, R., Pippen, J., Oldham, F., and Ando, D., Phase I trial of interferon gamma retroviral vector administered intratumorally with multiple courses in patients with metastatic melanoma, Hum. Gene Ther., 10, 1289, 1999.
16. DePolo, N.J., Harkleroad, C. E., Bodner, M., Watt, A. T., Anderson, C. G., Greengard, J. S., Murthy, K. K., Dubensky, T. W., and Jolly, D. J., The resistance of retroviral vectors produced from human cells to serum inactivation in vivo and in vitro is primate species dependent, J. Virol, 73, 6708, 1999.
17. Cosset, F-L., Takeuchi, Y., Battini, J-L., Weiss, R. A., and Collins, M. K. L., High-titer packaging cells producing recombinant retroviruses resistant to human serum, J. Virol., 69, 7430, 1995.
18. McCormack, J. E., Martineau, D., DePolo, N., Maifert, S., Akbarian, L., Townsend, K., Lee, W., Irwin, M., Sajjadi, N., Jolly, D.J., and Warner, J., Anti-vector immunoglobulin induced by retroviral vectors, Hum. Gene Ther., 8, 1263, 1997.
19. Martineau, D., Klump, W. M., McCormack, J. E., DePolo, N.J., Kamantigue, E., Petrowski, M., Hanlon, J., Jolly, D.J., Mento, S.J., and Sajjadi, N., Evaluation of PCR and ELISA assays for screening clinical trial subjects for replication-competent retrovirus, Hum. Gene Ther., 8, 1231, 1997.
20. Karavodin, L. M., Robbins, J., Chong, K., Hsu, D., Ibanez, C., Mento, S., Jolly, D., and Fong, T. C., Generation of a systemic anti-tumor response with regional intratumoral injections of interferon γ retroviral vector, Hum. Gene Ther., 9, 2231, 1998.
21. Kruse, C. A., Roper, M. D., Kleinschmidt-DeMasters, B. K., Banuelos, S. J., Smiley, W. R., Robbins, J. M., and Burrows, F. J., Purified herpes simplex thymidine kinase retrovector particles, I. In vitro characterization, in situ transduction efficiency, and histopathological analyses of gene therapy-treated brain tumors, Cancer Gene Ther., 4, 118, 1997.
22. Greengard, J. S. and jolly, D.J., Animal testing of retroviral-mediated gene therapy for factor VIII deficiency, Thromb. Haemost., 82, 555, 1999.
23. Irwin, M. J., Laube, L. S., Lee, V., Austin, M., Chada, S., Anderson, C. G., Townsend, K., Jolly, D. J., and Warner, J. F., Direct injection of a recombinant retroviral vector induces human immunodeficiency virus-specific immune responses in mice and nonhuman primates, J. Virol., 68, 5036, 1994.
24. Sallberg, M., Hughes, J., Javadian, A., Ronlov, G., Hultgren, C., Townsend, K., Anderson, C. G., O'Dea, J., Alfonso, J., Eason, R., Murthy, K. K., Jolly, D. J., Chang, S. M., Mento, S. J., Milich, D., and Lee, W. T., Genetic immunization of chimpanzees chronically infected with the hepatitis B virus, using a recombinant retroviral vector encoding hepatitis B virus core antigen, Hum. Gene Ther., 9, 1719, 1998.
25. Warner, J. F., Jolly, D. J., and Merrit, J., Human immunodeficiency virus immunotherapy using a retroviral vector, Curr. Topics Microbiol. Immunol., 226, 145, 1998.
26. Ghivizzani, S. C., Lechman, E. R., Tio, C., Mule, K. M., Chada, S., McCormack, J. E., Evans, C. H., and Robbins, P. D., Direct retrovirus-mediated gene transfer to the synovium of the rabbit knee: Implications for arthritis gene therapy, Gene Ther., 4, 977, 1997.
27. Nguyen, K. H., Boyle, D. L., McCormack, J. E., Chada, S., Jolly, D. J., and Firestein, G. S., Direct synovial gene transfer with retroviral vectors in rat adjuvant arthritis, J. Rheumatol, 25, 1118, 1998.
28. Smiley, W. R., Laubert, B., Howard, B. D., Ibanez, C., Fong, T. C., Summers, W. S., and Burrows, F. J., Establishment of parameters for optimal transduction efficiency and antitumor effects with purified high-titer HSV-TK retroviral vector in established solid tumors, Hum. Gene Ther., 8, 965, 1997.
29. Taichman, L. B., Systemic replacement therapy from genetically modified epidermal keratinocytes, Proc. Assoc. Am. Physicians, 111, 206, 1999.
30. Kolodka, T. M., Finegold, M., Kay, M. A., and Woo, S. L., Hepatic gene therapy: efficient retroviral-mediated gene transfer into rat hepatocytes in vivo, Somat. Cell Mol. Genet., 19, 491, 1993.
31. Bosch, A., McCray, Jr., P. B., Chang, S. M., Ulich, T. R., Simonet, W. S., Jolly, D. J., and Davidson, B. L., Proliferation induced by keratinocyte growth factor enhances in vivo retroviral-mediated gene transfer to mouse hepatocytes, J. Clin. Invest., 98, 2683, 1996.
32. Wang, G., Davidson, B. L., Melchert, P., Slepushkin, V. A., van Es, H. H., Bodner, M., Jolly, D. J., and McCray, Jr., P. B., Influence of cell polarity on retrovirus-mediated gene transfer to differentiated human airway epithelia, J. Virol., 72, 9818, 1998.
33. Naldini, L., Blomer, U., Gallay, P., Ory, D., Mulligan, R., Gage, F. H., Verma, I. M., and Trono, D., In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector, Science, 272, 263, 1996.
34. Johnston, J. C., Gasmi, M., Lim, L. E., Elder, J. H., Yee, J-K., Jolly, D. J., Campbell, K. P., Davidson, B. L., amd Sauter, S. L., Minimum requirements for efficient transduction of dividing and nondividing cells by Feline Immunodeficiency Virus Vectors, J. Virol., 73, 4991, 1999.
35. Fielding, A. K., Maurice, M., Morling, F. J., Cosset, F. L., and Russell, S. J., Inverse targeting of retroviral vectors: Selective gene transfer in a mixed population of hematopoietic and nonhematopoietic cells, Blood, 91, 1802, 1998.
36. Jiang, A., Chu, T. H., Nocken, F., Cichutek, K., and Dornburg, R., Cell-type-specific gene tranfer into human cells with retroviral vectors that display single-chain antibodies, J. Virol., 72, 10148, 1998.
37. Molnar-Kimber, K. L., Sterman, D. H., Chang, M., Kang, E. H., El Bash, M., Lanuti, M., Elshami, A., Gelfand, K., Wilson, J. M., Kaiser, L. R., and Albelda, S. M., Impact of pre-existing and induced humoral and cellular immune responses in an adenovirus-based gene therapy phase I clinical trial for localized mesothelioma, Hum. Gene Ther., 9, 2121, 1998.
38. Yu, D. C., Sakamoto, G. T., and Henderson, D. R., Identification of the transcriptional regulatory sequences of human kallikrein 2 and their use in the construction of calydon virus 764, An attenuated replication competent adenovirus for prostate cancer therapy, Cancer Res., 59, 1498, 1999.
39. Douglas, J. T., Rogers, B. E., Rosenfeld, M. E., Michael, S. I., Feng, M., and Curiel, D. T., Targeted gene delivery by tropism-modified adenoviral vectors,Nat. Biotechnol., 14, 1574, 1996.
40. Wickham, T. J., Segal, D. M., Roelvink, P. W., Carrion, M. E., Lizonova, A., Lee, G. M., and Kovesdi, I., Targeted adenovirus gene transfer to endothelial and smooth muscle cells by using bispecific antibodies, J. Virol., 70, 6831, 1996.
41. Kirn, D., Hermiston, T., and McCormick, F., ONYX-015: Clinical data are encouraging, Nat. Med., 4, 1341, 1998.
42. Haynes, B. F., HIV vaccines: Where we are and where we are going, Lancet, 348, 933, 1996.
43. Polo, J. M., Belli, B. A., Driver, D. A., Frolov, I., Sherrill, S., Hariharan, M. J., Townsend, K., Perri, S., Mento, S. J., Jolly, D. J., Chang, S. M., Schlesinger, S., and Dubensky, Jr., T. W., Stable alphavirus packaging cell lines for Sindbis virus and Semliki Forest virus-derived vectors, Proc. Natl. Acad. Sci. USA, 96, 4598, 1999.
44. Friedmann, T., The Development of Human Gene Therapy, Cold Spring Harbor, NY: Cold Spring Harbor Laboratory, 1999.
45. Miller, A. D., Retrovirus packaging cells, Hum. Gene Ther., 1, 5, 1990.
46. Dornburg, R., Reticuloendotheliosis viruses and derived vectors, Gene Ther., 2, 301, 1995.
47. Miller, A. D., Garcia, J. V., von Suhr, N., Lynch, C. M., Wilson, C., and v. Eiden, M., Construction and properties of retrovirus packaging cells based on Gibbon Ape Leukemia Virus, J. Virol., 65, 2220, 1991.
48. Gasmi, M., Glynn, J., Jin, M. J., Jolly, D. J., Yee, J. K., and Chen, S. T., Requirements for efficient production and transduction of human immunodeficiency virus type 1-based vectors, J. Virol., 73, 1828, 1999.
49. Buchschacher, Jr., G. L., and Panganiban, A. T., Human immunodeficiency virus vectors for inducible expression of foreign genes, J. Virol., 66, 2731, 1992.
50. Kafri, T., van Praag, H., Ouyang, L., Gage, F. H., and Verma, I. M., A packaging cell line for lentivirus vectors, J. Virol., 73, 576, 1999.
51. Yee, J. K., Miyanohara, A., LaPorte, P., Bouic, K., Burns, J. C., and Friedmann, T., A general method for the generation of high-titer, pantropic retroviral vectors: Highly efficient infection of primary hepatocytes, Proc. Natl. Acad. Sci. USA, 91, 9564, 1994.
52. Zhang, J. and Temin, H. M., Retrovirus recombination depends on the length of sequence indentity and is not error prone, J. Virol., 68, 2409, 1994.
53. Sajjadi, N., Development of retroviral-based gene therapy products: A quality control perspective, Qual. Assur. J., 2, 113, 1997.
54. Printz, M., Reynolds, J., Mento, S. J., Jolly, D., Kowal, K. and Sajjadi, N., Recombinant retroviral vector interferes with the detection of amphotropic replication competent retrovirus in standard culture assays, Gene Ther., 2, 143, 1995.
55. Cone, R. D. and Mulligan, R. C., High-efficiency gene transfer into mammalian cells: Generation of helper-free recombinant retrovirus with broad mammalian host range, Proc. Natl. Acad. Sci. USA, 81, 6349, 1984.
56. Sorge, J., Wright, D., Erdman, V. D., and Cutting, A. E., Amphotropic retrovirus vector system for human cell gene transfer, Mol. Cell. Biol., 4, 1730, 1984.
57. Miller, A. D., Law, M. F., and Verma, I. M., Generation of helper-free amphotropic retroviruses that transduce a dominant-acting, methotrexate-resistant dihydrofolate reducatase gene, Mol. Cell. Biol., 5, 431, 1985.
58. Miller, A. D., Trauber, D. R., and Buttimore, C., Factors involved in production of helper virus-free retrovirus vectors, Somat. Cell Mol. Genet., 12, 175, 1986.
59. Danos, O. and Mulligan, R. C., Safe and efficient generation of recombinant retroviruses with amphotropic and ecotropic host ranges, Proc. Natl. Acad. Sci. USA, 85, 6460, 1988.
60. Markowitz, D., Goff, S., and Banks, A., Construction and use of a safe and efficient amphotropic packaging cell line, Virology, 167, 400, 1988.
61. Watanabe, S. and Ternin, H. M, Construction of a helper cell line for avian reticuloendotheliosis virus cloning vectors, Mol. Cell. Biol., 3, 2241, 1983.
62. Barber, J. R., Jolly, D. J., Respess, J. G., and Chang, S. M. W., Packaging cells, Patent Application WO 9205266 (1992).
63. Laube, L. S., Burrascano, M., Dejesus, C. E., Howard, B. D., Johnson, M. A., Lee, W. T., Lynn, A. E., Peters, G., Ronlov, G. S., and Townsend, K. S., Cytotoxic T lymphocyte and antibody responses generated in rhesus monkeys immunized with retroviral vector-transcluced fibroblasts expressing human immunodeficiency virus type-1 IIIB ENV/REV proteins, Hum. Gene Ther., 5, 853, 1994.
64. Howard, B., Burrascano, M., McCallister, T., Chong, K., Gangavalli, R., Severinsson, L, Jolly, D. J., Darrow, T., Vervaert, C., and Abdel-Wahab, Z., Retrovirus-mediated gene transfer of the human gamma-IFN gene: A therapy for cancer, Ann. NY Acad. Sci., 716, 167, 1994.
65. Blaese, R. M., Culver, K. W., Miller, A. D., Carter, C. S., Fleisher, T., Clerici, M., Shearer, G., Chang, L., Chiang, Y., and Tolstoshev, P., T lymphocyte directed gene therapy for ADA-SCID: Initial trial results after four years, Science, 270, 475, 1995.
66. Otto, E., Jones-Trower, A., Vanin, E. F., Stambaugh, K., Mueller, S. N., Anderson, W. F., and McGarrity, G. J., Characterization of a replication-competent retrovirus resulting from recombination of packaging and vector sequences, Hum. Gene Ther., 5, 567, 1994.
67. Coffin, J. M., Retrovirus variation and evolution, in The DNA provirus: Howard Temin's scientific legacy, Cooper, G. M., Greenberg Temin, R., and Sugden, B., Eds., Washington, DC: ASM Press, 1995, 221
68. Blond, J-L., Beseme, F., Duret, L., Bouton, O., Bedin, F., Perron, H., Mandrand, B., and Mallet, F., Molecular characterization and placental expression of HERV-W, a new human endogenous retrovirus family, J. Virol., 73, 1175, 1999.
69. Wilkinson, D. A., Goodchild, N. L., Saxton, T. M., Wood, S., and Mager, D. L., Evidence for a functional subclass of the RVL-H family of human endogenous retrovirus-like sequences, J. Virol., 67, 2981, 1993.
70. Jenkins, N. A., Copeland N. G., Taylor B. A., and Lee B. K., Organization, distribution, and stability of endogeneous ecotropic murine leukemia virus DNA in chromososmes of mus musculus, J. Virol., 43, 26, 1982.
71. Hatzoglou, M., Hodgson, C. P., Mularo, F., and Hanson, R. W., Efficient packaging of a specific VL30 retroelement by psi 2 cells which produce MoMLV recombinant retroviruses, Hum. Gene Ther., 1, 385, 1990.
72. Scadden, D. T., Fuller, B., and Cunningham, J. M., Human cells infected with retrovirus vectors acquire an endogenous murine provirus, J. Virol., 64, 424, 1990.
73. Chong, H. and Vile, R. G., Replication-competent retrovirus produced by a "split-function" third-generation amphotropic packaging cell line, Gene Ther., 3, 624, 1996.
74. Chong, H., Starkey, W., and Vile, R. G., A replication-competent retrovirus arising from a split-function packaging cell line was generated by recombination events between the vector, one of the packaging constructs, and endogenous retroviral sequences, J. Virol., 72, 2663, 1998.
75. Bender, M. A., Palmer, T. D., Gelinas, R. E., and Miller, A. D., Evidence that the packaging signal of Moloney murine leukemia virus extends into the gag region, J. Virol., 61, 1639, 1987.
76. Morgenstern, J. P. and Land, H., Advanced mammalian gene transfer: High-titer retroviral vectors with multiple drug selection markers and a complementary helper-free packaging cell line, Nucl. Acids Res., 18, 3587, 1990.
77. Salmons, B. and Guenzburg, W. H., Targeting of retroviral vectors for gene therapy, Hum. Gene Ther., 4, 129, 1993.
78. Dzierzak, E. A., Papayannopoulou, T., and Mulligan, R. C., Lineage-specific expression of a human B-globin gene in murine bone marrow transplant recipients reconstituted with retrovirus-transduced stem cells, Nature, 331, 35, 1988.
79. Yu, S.-F., von Ruden, T., Kantoff, P. W., Garber, C., Seiberg, M., Ruther, U., Anderson, W. F., Wagner, E. F., and Gilboa, E., Self-inactivating retroviral vectors designed for transfer of whole genes into mammalian cells, Proc. Natl. Acad. Sci. USA, 83, 3194, 1986.
80. Yee, J.-K., Moores, J. C., Jolly, D. J., Wolff, J. A., Respess, J. G., and Friedmann, T., Gene expression from transcriptionally disabled retroviral vectors, Proc. Natl. Acad. Sci. USA, 84, 5197, 1987.
81. Delviks, K. A., Hu, W. S., and Pathak, V. K., Psi-vectors: Murine leukemia virus-based self-inactivating and self-activating retroviral vectors, J. Virol., 71, 6218, 1997.
82. Miyoshi, H., Blomer, U., Takahashi, M., Gage, F. H., and Verma, I. M., Development of self-inactivating lentivirus vector, J. Virol., 72, 8150, 1998.
83. Hantzopoulos, P. A., Sullenger, B. A., Ungers, G., and Gilboa, E., Improved gene expression upon transfer of the adenosine deaminase minigene outside the transcriptional unit of a retroviral vector, Proc. Natl. Acad. Sci. USA, 86, 3519, 1989.
84. Wiznerowicz, M., Fong, A. Z., Mackiewicz, A., and Hawley, R. G., Double-copy bicistronic retroviral vector platform for gene therapy and tissue engineering: Application to melanoma vaccine development, Gene Ther., 4, 1061, 1997.
85. Hawley, R. G., Sabourin, L. A., and Hawley, T. S., An improved retroviral vector for gene transfer into undifferentiated cells, Nucl. Acids Res., 17, 4001, 1989.
86. Anderson, W. F., McGarrity, G. J., and Moen, R. C., Report to the NIH Recombinant DNA Advisory Committee on murine replication-competent retrovirus (RCR) assays, Hum. Gene Ther., 4, 311, 1993.
87. McClure, M. A., Johnson, M. S., Feng, D.-F., and Doolittle, R. F., Sequence comparisons of retroviral proteins: Relative rates of change and general phylogeny, Proc. Natl. Acad. Sci., USA, 85, 2469, 1988
88. Moolten, F. L. and Cupples, L. A., A model for predicting the risk of cancer consequent to retroviral gene therapy, Hum. Gene, Ther., 3, 479, 1992.
89. Rigg, R. J., Chen, J., Dando, J. S., Forestell, S. P., Plavec, I., and Boehnlein, E., A novel human amphotropic packaging cell line: High titer, complement resistance, and improved safety, Virology, 218, 290, 1996.
90. JaVee, E. M., Dranoff, G., Cohen, L. K., Hauda, K. M., Clift, S., Marshall, F. F., Mulligan, R. C., and Pardoll, D. M., High efficiency gene tranfer into primary human tumor explants without cell selection, Cancer Res., 53, 2221, 1993.
91. Choulika, A., Guyot, V., and Nicolas, J. F., Transfer of single gene-containing long terminal repeats into the genome of mammalian cells by a retroviral vector carrying the ere gene and the loxP site, J. Virol., 70, 1792, 1996.
92. Miller, D. A., Trauber, D. R., and Buttimore, C., Factors involved in production of helper virus-free retrovirus vectors, Som. Cell Mol. Genet., 12, 175, 1986.
93. Hwang, S.-H. S. and Gilboa, E., Expression of genes introduced into cells by retroviral infection is more efficient than that of genes introduced into cells by DNA transfection, J. Virol., 50, 417, 1984.
94. Bodine, D. M., McDonagh, K. T., Brandt, S. J., Ney, P. A., Agricola, B., Byrne, E., and Nienhuis, A. W., Development of a high-titer retrovirus producer cell line capable of gene transfer into rhesus monkey hematopoietic stem cells, Proc. Natl. Acad. Sci. USA, 87, 3738, 1990.
95. + enriched cord blood and Gaucher bone marrow cells by a retroviral vector carrying the glucocerebrosidase gene, Gene Ther., 1, 176, 1994.
96. Kozak, S. L. and Kabat, D., Ping-pong amplification of a retroviral vector achieves high-level gene expression: Human growth hormone production, J. Virol., 64, 3500, 1990.
97. Hoatlin, M. E., Kozak, S. L., Spiro, C., and Kabat, D., Amplified and tissue-directed expression of retroviral vectors using ping-pong techniques, J. Mol. Med., 73, 113, 1995.
98. Lynch, C. M. and Miller, A. D., Production of high-titer helper virus-free retroviral vectors by co-cultivation of packaging cells with different host ranges, J. Virol., 65, 3887, 1991.
99. Bestwick, R. K., Kozak, S. L, and Kabat, D., Overcoming interference to retroviral super-infection results in amplified expression and transmission of cloned genes, Proc. Natl. Acad. Sci. USA, 85, 5404, 1988.
100. Bodine, D. M., McDonagh, K. T., Seidel, N. E., and Nienhuis, A. W., Development of a high-titer retrovirus producer cell line and strategies for retrovirus-mediated gene transfer into Rhesus monkey hematopoietic stem cells, Ann. NY Acad. Sci., 612, 415, 1990.
101. Kinsella, T. M. and Nolan, G. P., Episomal vectors rapidly and stably produce high-titer recombinant retrovirus, Hum. Gene Ther., 7, 1405, 1996.
102. Pear, W. S., Nolan, G., P., Scott, M. L., and Baltimore, D., Production of high-titer helper-free retroviruses by transient transfection, Proc. Natl. Acad. Sci. USA, 90, 8392, 1993.
103. Le Doux, J. M., Morgan, J. R. Snow, R.G., and Yarmush, M., Proteoglycans secreated by packaging cell lines inhibit retrovirus infection, J. Virol., 70, 6468, 1996.
104. Forestell, S. P., Bohnlein, E., and Rigg, R. J., Retroviral end-point titer is not predictive of gene transfer efficiency: Implications for vector production, Gene Ther., 2, 723, 1995.
105. Shen, B. Q., Clarke, M. F., and Palsson, B. Q., Kinetics of retroviral production from the amphotropic ψ CRIP murine producer cell line, Cytotechnology, 22, 185, 1996.
106. Moyer, M. P. and Moyer, R. C., Transfection and transformation of human and animal cells by recombinant DNA vectors: Issues relevant to use these substrates for the production of biologicals, Dev. Biol. Stand., 70, 91, 1989.
107. Horaud, F., Viral vaccines and residual cellular DNA, Biologicals, 23, 225, 1995.
108. Regan, P. J. and Petricciani, P. J., Risk of neoplastic transformation from cellular DNA: Calculations using the oncogene model, Dev. Biol. Stand., 68, 43, 1987.
109. Acceptability of cell substrates for production of biologicals, World Health Organization Technical Report Series No 747, 1987.
110. Expert Committee on biological standardization, Forty-Seventh Reporl, World Health Organization Technical Report Series No 878, 1998.
111. Wierenga, D. E., Cogan, J., and Petricciani, J. C., Administration of tumor cell chromatin to immunosuppressed and non-immunosuppressed non-human primates, Biologicals, 23, 221, 1995.
112. Duxbury, M., Jezuit, M., Letwin, B., and Wright, J., DNA in plasma of human blood for transfusion, Biologicals, 23, 229, 1995.
113. Brose, D., Dosmar, M., Gates, S., and Hutchison, F., Studies on the scale-up of crossflow filtration devices, PDA J. Pharm. Sci. Technol., 50, 252, 1996.
114. Paul, R. W., Morris, D., Hess, B. W., Dunn, J., and Overell, R. W., Increased viral titer through concentration of viral harvests from retroviral packaging lines, Hum. Gene Ther., 4, 609, 1993.
115. Sekhar, M., Kotoni, H., Doren, S., Agarwal, R., McGarrity, G., and Dunbar, C. E., Retroviral transduction of CD34-enriched hematopoietic cells under serum-free conditions, Hum. Gene Ther., 7, 33, 1996.
116. Bowles, N. E, Eisensmith, R. C., Mohuiddin, R., Pyron, M., and Woo, S.L.C., A simple and efficient method for the concentration and purification of recombinant retrovirus for increased hepatocyte transduction in vivo, Hum. Gene Ther., 7, 1735, 1996.
117. Seppen, J., Kimmel, R. J., and Osborne, W. R. A., Serum-free production, concentration, and purification of recombinant retroviruses, Biotechniques, 23, 788, 1997.
118. Burns, J. C., Friedman, T., Driever, W., Burrascano, M., and Yee, J. K., Vesicular stomatitis virus G glycoprotein pseudotyped retroviral vectors: Concentration to very high titer and efficient gene transfer into mammalian and non-mammalian cells, Proc. Natl. Acad. Sci. USA, 90, 8033, 1993.
119. Yee, J. K., Friedman, T., and Burns, J. C., Generation of high-titer pseudotyped retroviral vectors with very broad host range, Methods Cell Biol., 43A, 99, 1994.
120. McGrath, M., Witte, O., Pincus, T., and Weissman, I. L., Retrovirus purification: Method that conserves envelope glycoprotein and maximizes infectivity, J.Virol., 25, 923, 1978.
121. Herman, S. A. and Coffin, J. M., Efficient packaging of read-through RNA in ALV: Implications for oncogene transduction, Science, 236, 845, 1987.
122. Cullen, B. R., Lomedico, P. T., and Ju, G., Transcriptional interference in avain retroviruses -Implications for the promoter insertion model of leukaemogenesis,Nature, 307, 241, 1984.
123. Jolly, D. J., Esty, A. C., Subramani, S., Friedmann, T., and Verma, I. M., Elements in the long terminal repeat of murine retroviruses enhance stable transformation by thymidine kinase gene, Nucl. Acids Res., 11, 1855, 1983.
124. Emerman, M. and Temin, H. M., Genes with promoters in retrovirus vectors can be independently suppressed by an epigenetic mechanism, Cell, 39, 449, 1984.
125. Emerman, M. and Temin, H.M., Quantitative analysis of gene suppression in integrated retrovirus vectors, Mol. Cell. Biol., 6, 792, 1986.
126. Fassati, A., Bardoni, A., Sironi, M., Wells, D. J., Bresolin, N., Scarlato, G., Hatanaka, M., Yamaoka, S., and Dickson, G., Insertion of two independent enhancers in the long terminal repeat of a self-inactivating vector results in high-titer retroviral vectors with tissue-specific expression, Hum. Gene Ther., 9, 2459, 1998.
127. Gilboa, E., Retrovirus vectors and their uses in molecular biology, Bioessays, 5, 252, 1986.
128. Wu, X., Holschen, J., Kennedy, S.C., and Ponder, K.P., Retroviral vector sequences may interact with some internal promoters and influence expression, Hum. Gene Ther., 7, 159, 1996.
129. Olson, P., Nelson, S., and Dornburg, R., Improved self-inactivating retroviral vectors derived from spleen necrosis virus, J. Virol., 68, 7060, 1994.
130. Julias, J. G., Hash, D., and Pathak, V. K., E-vectors: Development of novel self-inactivating and self-activating retroviral vectors for safer gene therapy, J. Virol., 69, 6839, 1995.
131. Hwang, J. J., Li, L., and Anderson, W. F., Conditional self-inactivating retrovirus vector that uses a tetracycline-responsive expression system, J. Virol., 71, 7128, 1997.
132. Cooper, N. R., Jensen, F. C., Welsh, Jr., R. M., and Oldstone, M. B., Lysis of RNA tumor viruses by human serum: Direct antibody-independent triggering of the classical complement pathway, J. Exp. Med., 144, 970, 1976.
133. Lachman, P.J. and Davies, A., Complement and immunity to viruses, Immunol. Rev., 159, 69, 1997.
134. Takeuchi, Y., Cosset, F. L., Lachmann, P. J., Okada, H., Weiss, R. A., and Collins, M. K., Type C retrovirus inactivation by human complement is determined by both the viral genome and the producer cell, J. Virol., 68, 8001, 1994.
135. Rother, R. P., Fodor, W. L., Springhorn, J. P., Birks, C. W., Setter, E., Sandrin, M. S., Squinto, S. P., and Rollins, S. A., A novel mechanism of retrovirus inactivation in human serum mediated by anti-alpha-galactosyl natural antibody, J. Exp. Med., 182, 1345, 1995.
136. Rother, R. P. and Squinto, S. P., The alpha-galactosyl epitope: A sugar coating that makes viruses and cells unpalatable, Cell, 86, 185, 1996.
137. Montefiori, D. C., Cornell, R. J., Zhou, J. Y., Zhou, J. T., Hirsch, V. M., and Johnson, P. R., Complement control proteins, CD46, CD55, and CD59, as common surface constituents of human and simian immunodeficiency viruses and possible targets for vaccine protection, Virology, 205, 82, 1994.
138. Saifuddin, M., Hedayati, T., Atkinson, J. P., Holguin, M. H., Parker, C. J. and Spear, G. T., Human immunodeficiency virus type 1 incorporates both glycosyl phosphatidylinositol-anchored CD55 and CD59 and integral membrane CD46 at levels that protect from complement-mediated destruction, J. Gen. Virol., 78, 1907, 1997.
139. Pensiero, M. N., Wysocki, C. A., Nader, K., and Kikuchi, G. E., Development of amphotropic murine re trovirus vectors resistant to inactivation by human serum, Hum. Gene Ther., 7, 1095, 1996.
140. Miller, A. D., Cell-surface receptors for retroviruses and implications for gene transfer, Proc. Natl. Acad. Sci. USA, 93, 11407, 1996.
141. Yang, Y., Vanin, E. F., Whitt, M. A., Fornerod, M., Zwart, R., Schneiderman, R. D., Grosveld, G., and Nienhuis, A. W., Inducible, high-level production of infectious murine leukemia retroviral particles pseudotyped with vesicular stomatitis virus G envelope protein, Hum. Gene Ther., 6, 1203, 1995.
142. Rosenberg, S. A., Anderson, W. F., Blaese, M., Hwu, P., Yannelli, J. R., Yang, J. C., Topalian, S. L., Schwartzentruber, D. J., Weber, J. S., Ettinghausen, S. E., Parkinson, D. N., and White, D. E., The development of gene therapy for the treatment of cancer, Ann. Surg., 218, 455, 1993.
143. Tepper, R. I., Pattengale, P. K., and Leder, P., Murine interleukin-4 displays potent anti-tumor activity in vivo, Cell, 57, 503, 1989.
144. Dranoff, G. and Mulligan, R. C., Gene transfer as cancer therapy, Adv. Immunol., 58, 417, 1995.
145. Hurford, Jr., R. K., Dranoff, G., Mulligan, R. C., and Tepper, R. I., Gene therapy of metastatic cancer by in vivo retroviral gene targeting, Nat. Genet., 10, 430, 1995.
146. Russell, S. J., Hawkins, R. E., and Winter, G., Retroviral vectors displaying functional antibody fragments, Nucl. Acid Res., 21, 1081, 1993.
147. Kasahara, N., Dozy, A. M., and Kan, Y. W., Tissue-specific targeting of retroviral vectors through ligand-receptor interactions, Science, 266, 1373, 1994.
148. Cosset, F. L., Morling, F. J., Takeuchi, Y., Weiss, R. A., Collins, M., and Russell, S. J., Retroviral retargeting by envelopes expressing an N-terminal binding domain, J. Virol., 69, 6314, 1995.
149. Valsesia-Wittman, S., Morling, F. J., Nilson, B. H. K., Takeuchi, Y., Russell, S. J., and Cosset, F. L., Improvement of retroviral retargeting by amino acid spacers between an additional binding domain and the N terminus of moloney murine leukemia virus SU, J. Virol., 70, 2059, 1996.
150. Chadwick, M. P., Morling, F. J., Cosset, F. L., and Russell, S. J., Modification of retroviral tropism by display of IGF-I, J. Mol. Biol., 285, 485, 1999.
151. Martin, F., Kupsch, J., Takeuchi, Y., Russell, S., Cosset, F. L., and Collins, M., Retroviral vector targeting to melanoma cells by single-chain antibody incorporation in envelope, Hum. Gene Ther., 9, 737, 1998.
152. Nilson, B. H. K., Morling, F. J., Cosset, F. L., and Russell, S. J., Targeting of retroviral vectors through protease-substrate interactions, Gene Ther., 3, 280, 1996.
153. Schnierle, B. S. and Groner, B., Retroviral targeted delivery, Gene Ther., 3, 1069, 1996.
154. Cosset, F. L. and Russell, S. J., Targeting retrovirus entry, Gene Ther., 3, 946, 1996.
155. Yamauchi, M., Freitag, B., Khan, C., Dervin, B., and Barklis, E., Stem cell factor binding to retrovirus primer binding site silencers, J. Virol., 69, 1142, 1995.
156. Jaenisch, R., Schnieke, A., and Harbers, K., Treatment of mice with 5-azacytidine efficiently activates silent retroviral genomes in different tissues, Proc. Natl. Acad. Sci. USA, 82, 1451, 1985.
157. Walther, W. and Stein, U., Cell type specific and inducible promoters for vectors in gene therapy as an approach for cell targeting, J. Mol. Med., 74, 379, 1996.
158. Miller, N. and Whelan, J., Progress in transcriptionally targeted and regulatable vectors for genetic therapy, Hum. Gene Ther., 8, 803, 1997.
159. Chen, W. Y., Bailey, E. C., McCune, S. C., Dong, J. Y., and Townes, T. M., Reactivation of silenced, virally transduced genes by inhibitors of histone deacetylase, Proc. Natl. Acad. Sci. USA, 94, 5798, 1997.
160. Ponder, K. P., Dunbar, R. P., Wilson, D. R., Darlington, G. J., and Woo, S. L., Evaluation of relative promoter strength in primary hepatocytes using optimized lipofectin, Hum. Gene Ther., 2, 41, 1991.
161. Weichselbaum, R. R., Hallahan, D. E., Beckett, M. A., Mauceri, H. J., Lee, H., Sukhatme, V. P., and Kufe, D. W., Gene therapy targeted by radiation preferentially radiosensitizes tumor cell, Cancer Res., 54, 4266, 1994.
162. Hallahan, D. E., Mauceri, H. J., Seung, L. P., Dunphy, E. J., Wayne J. D., Hanna, N. N., Toledano, A., Hellman, S., Kufe, D. W., and Weichselbaum, R. R., Spatial and temporal control of gene therapy using ionizing radiation, Nat. Med., 1, 786, 1995.
163. Gossen, M. and Bujard, H., Tight control of gene expression in mammalian cells by tetra-cycline-responsive promoters, Proc. Natl. Acad. Sci. USA, 89, 5547, 1992.
164. Spencer, D. M., Wandless, T. J., Schreiber, S. L., and Crabtree, G. R., Controlling signal transduction with synthetic ligands, Science, 262, 1019, 1993.
165. No, D., Yao, T. P., and Evans, R. M., Ecdysone-inducible expression in mammalian cells and transgenic mice, Proc. Natl. Acad. Sci. USA, 93, 3346, 1996.
166. Rossi, F.M.V. and Blau, H.M., Recent advances in inducible gene expression systems, Curr. Opin. Biotechnol., 9, 451, 1998.
167. Paulus, W., Baur, I., Boyce, F. M., Breakefield, X. O., and Reeves, S. A., Self-contained, tertracycline-regulated retroviral vector system for gene delivery to mammalian cells, J. Virol., 70, 62, 1996.
168. Schwartzentruber, D. J., Biologic therapy with Interleukin-2: Clinical applications, in Biological Therapy of Cancer, 2nd Edition, DeVita, Jr., V. T., Hellmann, S., and Rosenberg, S. A., Eds., Philadelphia, PA: Lippincott, 1995, 235.
169. Quesada, J. R., Biologic therapy with Interferon-γ, in Biological Therapy of Cancer 2nd Edition, DeVita, Jr., V. T., Hellmann, S., and Rosenberg, S. A., Eds., Philadelphia, PA: Lippincott, 1995, 435.
170. Miller, L. L., Colony-Stimulating Factors: Clinical Applications, in Biological Therapy of Cancer 2nd Edition, DeVita, Jr., V. T., Hellmann, S., and Rosenberg, S. A., Eds., Philadelphia, PA: Lippincott, 1995, 141.
171. Fraker, D. L., Alexander, H. R., and Pass, H. I., Biologic therapy with TNF: Systemic administration and isolation-perfusion, in Biological Therapy of Cancer 2nd Edition, De Vita, Jr., V. T., Hellmann, S., and Rosenberg, S. A., Eds., Philadelphia, PA: Lippincott, 1995, 329.
172. Truitt, R. L., Keeveir, C. A., and Borden, E. C., Role of IL-4, IL-6, and
173. Rosenberg S.A., The immunotherapy of solid cancers based on cloning the genes encoding tumor rejection antigens, Ann. Rev. Med., 47, 481, 1996.
174. Bruton, J. K. and Koeller, J. M., Recombinant interleukin-2, Pharmacotherapy, 14, 635, 1994.
175. de Vries, J. E. and Spits, H., Cloned human cytotoxic T lymphocyte (CTL) lines reactive with autologous melanoma cells, I. In vitro generation, isolation, and analysis to phenotype and specificity, J. Immunol., 132, 510, 1984.
176. Anichini A., Fossati, G., and Parmiani, G., Clonal analysis of cytotoxic T-lymphocyte response to autologous human metastatic melanoma, Int. J. Cancer, 35, 683, 1985.
177. Anichini, A., Mazzocchi, A., Fossati, G., and Parmiani, G., Cytotoxic T lymphocyte clones from peripheral blood and from tumor site detect intratumor heterogeneity of melanoma cells; Analysis of specificity and mechanisms of interaction, J. Immunol., 142, 3692, 1989.
178. Kono, K., Rongcun, Y., Charo, J., Ichihara, F., Celis, E., Sette, A., Appella, E., Sekikawa, T., Matsumoto, Y., and Kiessling, R., Identification of HER2/neu-derived peptide epitopes recognized by gastric cancer-specific cytotoxic T lymphocytes, Int. J. Cancer, 78, 202, 1998.
179. Peiper, M., Goedegebuure, P. S., Linehan, D. C., Ganguly, E., Douville, C. C., and Eberlein, T. J., The HER2/neu-derived peptide is a tumor-associated antigen in human pancreatic cancer recognized by cytotoxic T lymphocytes, Eur. J. Immunol., 27, 1115, 1997.
180. Linehan, D. C., Goedegebuure, P. S., Peoples, G. E., Rogers, S. O., and Eberlein, T. J., Tumor-specific and HLA-A2-restricted cytolysis by tumor-associated lymphocytes in human metastatic breast cancer, J. Immunol., 155, 4486, 1995.
181. Brouwenstijn, N., Gaugler, B., Kruse, K. M., van der Spek, C. W., Mulder, A., Osanto, S., van den Eynde, B. J., and Schrier, P. I., Renal-cell carcinoma-specific lysis by cytotoxic T-lymphocyte clones isolated from peripheral blood lymphocytes and tumor-infiltrating lymphocytes, Int. J. Cancer, 68, 177, 1996.
182. Bernhard, H., Maeurer, M. J., Jager, E., Wolfel, T., Schneider, J., Karbach, J., Seliger, B., Huber, C., Storkus, W. S., Lotze, M. T., Meyer zumBuschenfelde, K. H., and Knuth, A., Recognition of human renal cell carcinoma and melanoma by HLA-A2-restricted cytotoxic T lymphocytes is mediated by shared peptide epitopes and up-regulated by interferon-gamma, Scand. J. Immunol., 44, 285, 1996.
183. Ioannides, C. G., Fisk, B., Pollack, M. S., Frazier, M. L., Taylor Wharton, J., and Freednian, R. S., Cytotoxic T-cell clones isolated from ovarian tumour infiltrating lymphocytes recognize common determinants on non-ovarian tumour clones, Scand. J. Immunol., 37, 413, 1993.
184. Shiloni, E., Lafreniere, R., Mule, J.J., Schwarz, S. L., and Rosenberg, S. A., Effect of immunotherapy with allogeneic lymphokine-activated killer cells and recombinant interleukin 2 on established pulmonary and hepatic metastases in mice, Cancer Res., 46, 5633, 1986.
185. Nakamura, Y., Wakimoto, H., Abe, J., Kanegae, Y., Saito, I., Aoyagi, M., Hirakawa, K., and Hamada, H., Adoptive immunotherapy with murine tumor-specific T lymphocytes engineered to secrete interleukin 2, Cancer Res., 54, 5757, 1994.
186. Kim, S. J., Sadelain, M., Lee, J. S., Seong, R. H., Yun, Y. S., Jang, Y. J., and Chung, H. Y., Adoptive-transfer therapy of tumors with the tumor-specific primary cytotoxic T cells induced in vitro with the B7.1-transduced MCA205 cell line, Cancer Immunol. Immunother., 47, 257, 1999.
187. Gautam, S. C., Chikkala, N. F., Lewis, I., Grabowski, D. R., Finke, J. H., and Ganapathi, R., Therapeutic efficacy of interleukin-2 activated killer cells against adriamycin resistant mouseB16-BL6 melanoma, Anticancer Res., 12, 921, 1992.
188. Abe, J., Wakimoto, H., Tsunoda, R., Okabe, S., Yoshida, Y., Aoyagi, M., Hirakawa, K., and Hamada, H., In vivo anti-tumor effect of cytotoxic T lymphocytes engineered to produce interferon-gamma by adenovirus-mediated genetic transduction,Biochem. Biophys. Res. Commun., 218, 164, 1996.
189. Hornung, R. L., Longo, D. L., Bowersox, O. C., and Kwak, L. W., Tumor antigen-specific immunization of bone marrow transplantation donors as adoptive therapy against established tumor, J. Natl. Cancer Inst., 87, 1289, 1995.
190. Rosenberg, S. A., Lotze, M. T., Yang, J. C., Topalian, S. L., Chang, A. E., Schwartzentruber, D. J., Aebersold, P., Leitman, S., Linehan, W. M., Seipp, C. A., White, D. D., and Steinberg, S. M., Prospective randomized trial of high-dose interleukin-2 alone or in conjunction with lymphokine-activated killer cells for the treatment of patients with advanced cancer, J. Natl. Cancer Inst., 85, 622, 1993.
191. Topalian, S. L., Solomon, D., Avis, F. P., Chang, A. E., Freerksen, D. L., Linehan, W. M., Lotze, M. T., Robertson, C. N., Seipp, C. A., Simon, P., Simpson, C. G., and Rosenberg, S. A., Immunotherapy of patients with advanced cancer using tumor-infiltrating lymphocytes and recombinant interleukin-2: a pilot study, J. Clin. Oncol., 6, 839, 1988.
192. Kruse, C. A., Cepeda, L., Owens, B., Johnson, S. D., Stears, J., and Lillehei, K. O., Treatment of recurrent glioma with intracavitary alloreactive cytotoxic T lymphocytes and interleukin-2, Cancer Immunol. Immunother., 45, 77, 1997.
193. Haruta, I., Yamauchi, K., Aruga, A., Komatsu, T., Takasaki, K., Hayashi, N., and Hanyu, F., Analytical study of the clinical response to two distinct adoptive immunotherapies for advanced hepatocellular carcinoma: Comparison between LAK cell and CTL therapy, J. Immunother. Emphasis Tumor Immunol., 19, 218, 1996.
194. Yeung, R. S., Vollmer, C., Taylor, D. D., Palazzo, J., and Weese, J.L., Intratumoral rIL2-based immunotherapy in B16 melanoma, J. Surg. Res., 53, 203, 1992.
195. Faradji, A., Bohbot, A., Schmitt-Goguel, M., Roeslin, N., Dumont, S., Wiesel, M. L., Lallot, C., Eber, M., Bartholeyns, J., Poindron, P., Morand, G., Witz, J.-P., and Oberling, F., Phase I trial of intravenous infusion of ex-vivo-activated autologous blood-derived macrophages in patients with non-small-cell lung cancer: Toxicity and immunomodulatory effects, Cancer Immunol. Immunother., 33, 319, 1991.
196. Bernstein, Z. P., Goldrosen, M. H., Vaickus, L., Friedman, N., Watanabe, H., Rahman, R., Park, J., Arbuck, S. G., Sweeney, J., Vesper D. S., Takita, H., Zeffren, J., Dennin, R. A., and Foon, K. A., Interleukin-2 with ex vivo activated killer cells: Therapy of advanced non-small-cell lung caincer, J. Immunother., 10, 383, 1991.
197. Andreesen, R., Scheibenbogen, C., Brugger, W., Krause, S., Meerpohl, H. G., Leser, H. G., Engler, H., and Lohr G. W., Adoptive transfer of tumor cytotoxic macrophages generated in vitro from circulating blood monocytes: A new approach to cancer immunotherapy, Cancer Res., 50, 7450, 1990.
198. Farrar, A. and Schreiber, R. D., The molecular cell biology of interferon-gamma and its receptor, Ann. Rev. Immunol., 11, 571, 1993.
199. Watanabe, Y., Kuribayashi, K., Miyatake, S., Nishihara, K., Nakayama, E., Taniyama, T., and Sakata, T., Exogenous expression of mouse interferon gamma cDNA in mouse neuroblastoma C1300 cells results in reduced tumorigenicity by augmented anti-tumor immunity, Proc. Natl. Acad. Sci. USA, 86, 9456, 1989.
200. Gansbacher, B., Bannerji, R., Daniels, B., Zier, K., Cronin, K., and Gilboa, E., Retroviral vector-mediated gamma-interferon gene transfer into tumor cells generates potent and long lasting anti-tumor immunity, Cancer Res., 50, 7820, 1990.
201. + T cells against the wild-type tumor: Correlation with antigen presentation capability, J. Exp. Med., 175, 1423, 1992.
202. Porgador, A., Bannerji, R., Watanabe, Y., Feldman, M., Gilboa, E., and Eisenbach, L. J., Antimetastatic vaccination of tumor-bearing mice with two types of IFN-gamma gene-inserted tumor cells, Immunology, 150, 1458, 1993.
203. McAdam, J., Pulaski, B. A., Storozynsky, E., Yeh, K. Y., Sickel, J. Z., Frelinger, J. G., and Lord, E. M., Analysis of the effect of cytokines (interleukins 2,3,4, and 6, granulocyte-monocyte colony-stimulating factor, and interferon-gamma) on generation of primary cytotoxic T lymphocytes against a weakly immunogenic tumor. Cell Immunol., 165, 183, 1995.
204. Abdel-Wahab, Z. A., Osanto, S., Darrow, T. L., Barber, J. R., Vervaert, C. E., Gangavalli, R., McCallister, T. J., and Seigler, H. F., Transduction of human melanoma cells with the gamma interferon gene enhances cellular immunity, Cancer Gene Ther., 1, 171, 1994.
205. Cornetta, K., Berebitsky, D., Behnia, M., Traycoff, C., Srour, E. F., and Sledge, G. W., A retroviral vector expressing human interferon gamma upregulates MHC antigen expression in human breast cancer and leukemia cell lines, Cancer Gene Ther., 1, 91, 1994.
206. Gastl, G., Finstad, G. L., Guarini, A., Bosl, G., Gilboa, E., Bander, N. H., and Gansbacher, B., Retroviral vector-mediated lymphokine gene transfer into human renal cancer cells, Cancer Res, 52, 6229, 1992.
207. Ucar, K., Seeger, R. C., Challita, P. M., Watanabe, C. T., Yen, T. L., Morgan, J. P., Amado, R., Chou, E., McCallister, T., Barber, J. R., Jolly, D. J., Reynolds, C. P., Gangavalli, R., and Rosenblatt, J. D., Sustained cytokine production and immunophenotypic changes in human neuroblastoma cell lines transduced with a human gamma interferon vector, Cancer Gene Ther., 2, 171, 1995.
208. Weber, S. and Rosenberg, S. A., Modulation of murine tumor major histocompatibility antigens by cytokines in vivo and in vitro, Cancer Res., 48, 5818, 1988.
209. Neumann, H., Schmidt, H., Cavalie, A., Jenne, D., and Werkerle, H., Major histocompatibility complex (MHC) class I gene expression in single neurons of the central nervous system: Differential regulation by interferon (IFN)-gamma and tumor necrosis factor (TNF)-alpha, J. Exp. Med., 185, 305, 1997.
210. McAdam, J., Pulaski, B. A., Storozynsky, E., Yeh, K. Y., Sickel, J. Z., Frelinger, J. G., and Lord, E. M., Analysis of the effect of cytokines (interleukins 2,3,4, and 6, granulocyte-monocyte colony-stimulating factor, and interferon-gamma) on generation of primary cytotoxic T lymphocytes against a weakly immunogenic tumor, Cell Immunol., 165, 183, 1995.
211. Raes, G., Geldhof, A., Vanden Driessche, T., Opdenakker, G., Sibille, C., and De Baetselier, P., Immunogenization of a murine T-cell lymphoma via transfection with interferon-gamma, Leukemia, 9, Suppl. 1, S121, 1995.
212. + HLA-class I-restricted cytotoxic T cell clones with long-term assay and pretreatment of targets with interferon-gamma, Cancer Immunol. Immunother., 37, 187, 1993.
213. Siegler, H., Darrow, T. L., Abdel-Wahab, Z., Gangavalli, R., and Barber, J., A phase I trial of human gamma interferon transduced autologous tumor cells in patients with disseminated malignant melanoma, Hum. Gene Ther., 5, 761, 1994.
214. Ratliff, L., Kadmon, D., Shapiro, A., Jacobs, A.J., and Heston, W. D., Inhibition of mouse bladder tumor proliferation by murine interferon-gamma and its synergism with interferon-beta, Cancer Res., 44, 4377, 1984.
215. Blalock, E., Georgiades, J. A., Langford, M. P., and Johnson, H. M., Purified human immune interferon has more potent anticellular activity than fibroblast or leukocyte interferon, Cell Immunol., 49, 390, 1980.
216. Möbus, J., Asphal, W., Knapstein, P. G., and Kreienberg, R., Effects of interferon gamma on the proliferation and modulation of cell-surface structures of human ovarian carcinoma cell lines, J. Cancer Res. Clin. Oncol., 120, 27, 1993.
217. Doherty, M., Tsung, K., McCluskey, B., and Norton, J. A., Endogenous interferon-gamma acts directly on tumor cells in vivo to suppress growth, J. Surg. Res., 64, 68, 1996.
218. Young, M. R., Wright, M. A., Lozano, Y., Matthews, J. P., Benefield, J., and Prechel, M. M., Mechanisms of immune suppression in patients with head and neck cancer: Influence on the immune infiltrate of the cancer, Int. J. Cancer, 67, 333, 1996.
219. Alleva, D. G., Burger, C. J., and Elgert, K. D., Tumor-induced regulation of suppressor macrophage nitric oxide and TNF-alpha production; Role of tumor-derived IL-10, TGF-beta, and prostaglandin E2, J. Immunol., 153, 1674, 1994.
220. Kaido, T., Bandu, M. T., Maury, C., Ferrantini, M., Belardelli, F., and Gresser, I., IFN-alpha 1 gene transfection completely abolishes the tumorigenicity of murine B16 melanoma cells in allogeneic DBA/2 mice and decreases their tumorigenicity in syngeneic C57BL/6mice, Int. J. Cancer, 60, 221, 1995.
221. + T cell-mediated tumor rejection and development of anti-tumor immunity; Comparative studies with IFN-gamma-producing TS/A cells, J. Immunol., 153, 4604, 1994.
222. Ferrantini, M., Proietti, E., Santodonato, L., Gabriele, L., Peretti, M., Plavec, I., Meyer, F., Kaido, T., Gresser, I., and Belardelli, F., Alpha 1-interferon gene transfer into metastatic Friend leukemia cells abrogated tumorigenicity in immunocompetent mice: Anti-tumor therapy by means of interferon-producing cells, Cancer Res., 53, 1107, 1993.
223. Dong, Z., Juang, S. H., Kumar, R., Eue, I., Xie, K., Bielenberg, D., Lu, W., Bucana, C., Yang, X., and Fidler, I.J., Suppression of tumorigenicity and metastasis in murine UV-2237 fibrosarcoma cells by infection with a retroviral vector harboring the interferon-beta gene, Cancer Immunol. Immunother., 46, 137, 1998.
224. Yanagihara, K., Seyama, T., and Watanabe, Y., Anti-tumor potential of interferon-gamma: Retroviral expression of mouse interferon-gamma cDNA in two kinds of highly metastatic mouse tumor lines reduces their tumorigenicity, Nat. Immun., 13, 102, 1994.
225. Panelli, M. C., Wang, E., Shen, S., Schluter, S. F., Bernstein, R. M., Hersh, E. M., Stopeck, A., Gangavalli, R., Barber, J., Jolly, D., and Akporiaye, E. T., Interferon gamma (IFNgamma) gene transfer of an EMT6 tumor that is poorly responsive to IFNgamma stimulation: Increase in tumor immunogenicity is accompanied by induction of a mouse class II transactivator and class II MHC, Cancer Immunol. Immunother., 42, 99, 1996.
226. Porgador, A., Gansbacher, B., Bannerji, R., Tzehoval, E., Gilboa, E., Feldman, M., and Eisenbach, L., Anti-metastatic vaccination of tumor-bearing mice with IL-2-gene-inserted tumor cells, Int. J. Cancer, 53, 471, 1993.
227. Gansbacher, B., Zier, K., Daniels, B., Cronin, K., Bannerji, R., and Gilboa, E., Interleukin 2 gene transfer into tumor cells abrogates tumorigenicity and induces protective immunity, J. Exp. Med., 172, 1217, 1990.
228. Zier, K. S., Salvadori, S., Cronin, K. C., and Gansbacher, B., Vaccination with IL-2-secreting tumor cells stimulates the generation of IL-2-responsive T cells and prevents the development of unresponsiveness, Cancer Gene Ther., 1, 43, 1994.
229. Tseng, S. H., Hwang, L. H., and Lin, S. M., Induction of anti-tumor immunity by intracerebrally implanted rat C6 glioma cells genetically engineered to secrete cytokines, J. Immunother., 20, 334, 1997.
230. Kopantzev, E., Roschke, V., and Rudiko, V. S., Interleukin-2-mediated modulation of plasma cell tumor growth in a model of multiple myeloma, Hum. Gene Ther., 9, 13, 1998.
231. Hsieh, C. L., Pang, V. F., Chen, D. S., and Hwang, L. H., Regression of established mouse leukemia by GM-CSF-transduced tumor vaccine: Implications for cytotoxic T lymphocyte responses and tumor burdens, Hum. Gene Ther., 8, 1843, 1997.
232. Abe, J., Wakimoto, H., Yoshida, Y., Aoyagi, M., Hirakawa, K., and Hamada, H., Antitumor effect induced by granulocyte/macrophage-colony-stimulating factor gene-modified tumor vaccination: Comparison of adenovirus-and retrovirus-mediated genetic transduction, J. Cancer Res. Clin. Oncol., 121, 587, 1995.
233. Sanda, M. G., Ayyagari, S. R. JaVee, E. M., Epstein, J. I., Clift, S. L., Cohen, L. K., Dranoff, G., Pardoll, D. M., Mulligan, R. C., and Simons, J. W., Demonstration of a rational strategy for human prostate cancer gene therapy, J. Urol., 151, 622, 1994.
234. Colombo, M. P., Ferrari, G., Stoppacciaro, A., Parenza, M., Rodolfo, M., Mavilio, F., and Parmiani, G., Granulocyte colony-stimulating factor gene transfer suppresses tumorigenicity of a murine adenocarcinoma in vivo, J. Exp. Med., 173, 889, 1991.
235. Walther, W., Stein, U., and Pfeil, D., Gene transfer of human TNF alpha into glioblastoma cells permits modulation of mdrl expression and potentiation of chemosensitivity, Int. J. Cancer, 61, 832, 1995.
236. Myers, J. N., Mank-Seymour, A., Zitvogel, L., Storkus, W., Clarke, M., Johnson, C. S., Tahara, H., and Lotxe, M. T., Interleukin-12 gene therapy prevents establishment of SCC VII squamous cell carcinomas, inhibits tumor growth, and elicits long-term anti-tumor immunity in syngeneic C3H mice, Laryngoscope, 108, 261, 1998.
237. Colombo, M. P., Vagliani, M., Spreafico, F., Parenza, M., Chiodoni, C., Melani, C., and Stoppacciaro, A., Amount of interleukin 12 available at the tumor site is critical for tumor regression, Cancer Res., 56, 2531, 1996.
238. Tahara, H., Zitvogel, L., Storkus, W. J., Zeh, III, H. J., McKinney, T. G., Schreiber, R. D., Gubler, U., Robbins, P. D., and Lotze, M. T., Effective eradication of established murine tumors with IL-12 gene therapy using a polycistronic retroviral vector, J. Immunol., 154, 6466, 1995.
239. Jadus, M. R., Irwin, M. C., Irwin, M. R., Horansky, R. D., Sekhon, S., Pepper, KA., Kohn, D. B., and Wepsic, H. T., Macrophages can recognize and kill tumor cells bearing the membrane isoform of macrophage colony-stimulating factor, Blood, 87, 5232, 1996.
240. Bausero, M. A., Panoskaltsis-Mortari, A., Blazar, B. R., and Katsanis, E., Effective immunization against neuroblastoma using double-transduced tumor cells secreting GM-CSF and interferon-gamma, J. Immunother. Emphasis Tumor Immunol., 19, 113, 1996.
241. Rosenthal, F. M., Cronin, K., Bannerji, R., Golde, D. W., and Gansbacher, B., Augmentation of anti-tumor immunity by tumor cells transduced with a retroviral vector carrying the interleukin-2 and interferon-gamma cDNAs, Blood, 83, 1289, 1998.
242. Hsieh, C. L., Pang, V. F., Chen, D. S., and Hwang, L. H., Regression of established mouse leukemia by GM-CSF-transduced tumor vaccine: Implications for cytotoxic T lymphocyte responses and tumor burdens, Hum. Gene Ther., 8, 1843, 1997.
243. Parney, I. F., Petruk, K. C., Zhang, C., Farr-Jones, M., Sykes, D. B., and Chang, L. J., Granulocyte-macrophage colony-stimulating factor and B7-2 combination immunogene therapy in an allogeneic Hu-PBL-SCID/beige mouse-human glioblastoma multiforme model, Hum. Gene Ther., 8, 1073, 1997.
244. Tahara, H., Zitvogel, L., Storkus, W. J., Robbins, P. D., and Lotze, M. T., Murine models of cancer cytokine gene therapy using interleukin-12, Ann. N.Y. Acad. Sci., 795, 275, 1996.
245. Katsanis, E., Orchard, P. J., Bausero, M. A., Gorden, K. B., McIvor, R. S., and Blazar, B. R., Interleukin-2 gene transfer into murine neuroblastoma decreases tumorigenicity and enhances systemic immunity causing regression of preestablished retroperitoneal tumors, J. Immunother. Emphasis Tumor Immunol., 15, 81, 1994.
246. Bubenik, J., Voitenok, N. N., Kieler, J., Prassolov, V. S., Chumakov, P. M., Bubenikova, D., Simova, J., and Jandlova, T., Local administration of cells containing an inserted IL-2 gene and producing IL-2 inhibits growth of human tumours in nu/nu mice, Immunol. Lett., 19, 279, 1988.
247. Tjuvajev, J., Gansbacher, B., Desai, R., Beattie, B., Kaplitt, M., Matei, C., Koutcher, J., Gilboa, E., and Blasberg, R., RG-2 glioma growth attenuation and severe brain edema caused by local production of interleukin-2 and interferon-gamma, Cancer Res., 55, 1902, 1995.
248. Ram, Z., Walbridge, S., Heiss, J. D., Culver, K. W., Blaese, R. M., and Oldfield, E. H., In vivo transfer of the human interleukin-2 gene: Negative tumoricidal results in experimental brain tumors, J. Neurosurg., 80, 535, 1994.
249. Nemunaitis, J., Bohart, C. Fong, T. C., Meyer, W., Edelman, G., Paulson, R. S., Orr, D., Jain, V., O'Brien, J., Kuhn, J., Kowal, K., Burkeholder, S., Bruce, J., Ognoskie, N., Wynne, D., Martineau, D., and Ando, D., Phase I trial of retroviral vector mediated Interferon-γ gene transfer into autologous tumor cells in patients with metastatic melanoma, Cancer Gene Ther., 5, 292, 1998.
250. Nayak, S. K., McCallister, T., Han, L. J., Gangavalli, R., Barber, J., and Dillman, R. O., Transduction of human renal carcinoma cells with human gamma-interferon gene via retroviral vector, Cancer Gene Ther., 3, 143, 1996.
251. Seeger, R. C., Rosenblatt, J. D., Duerst, R. E., Reynolds, C. P., Villablanca, J. G., Hasenauer, B., and Feig, S. A., A Phase I study of human gamma interferon gene-transduced tumor cells in patients with neuroblastoma, Hum. Gene Ther., 9, 379, 1998.
252. + T-cell immunity, Cancer Gene Ther., 5, 321, 1998.
253. Parker, S. E., Anderson, D., Khatibi, S., Yankauckas, D., Saffran, D., Manthorpe, M., Margalith, M., Barnhart, K., Abai, A., and Hobart, P., Plasmid DNA gene therapy: Studies with the human in terleukin-2 gene in tumor cells in vitro and in the murine B16 melanoma model in vivo, Cancer Gene Ther., 3, 175, 1996.
254. O'Malley, W., Cope, K. A., Chen, S. H., Li, D., Schwarta, M. R., and Woo, S. L., Combination gene therapy for oral cancer in a murine model, Cancer Res., 56, 1737, 1996.
255. Kwong, L., Chen, S. H., Kosai, K., Finegold, M. J., and Woo, S. L., Adenoviral-mediated suicide gene therapy for hepatic metastases ofbreast cancer, Cancer Gene Ther., 3, 399, 1996.
256. Sutton, A., Berkman, S. A., Chen, S. H., Block, A., Dang, T. D., Kattan, M. W., Wheeler, T. M., Rowley, D. R., Woo, S. L., and Lerner, S. P., Adenovirus-mediated suicide gene therapy for experimental bladder cancer, Urology, 49, 173, 1997.
257. Toloza, M., Hunt, K., Swisher, S., McBride, W., Lau, R., Pang, S., Rhoades, K., Drake, T., Belldegrun, A., Glaspy, J., and Economou, J., In vivo cancer gene therapy with a recombinant interleukin-2 adenovirus vector, Cancer Gene Ther., 3, 11, 1996.
258. Addison, L., Braciak, T., Ralston, R., Muller, W. J., Gauldie, J., and Graham, F. L., Intratumoral injection of an adenovirus expressing interleukin 2 induces regression and immunity in a murine breast cancer model, Proc. Natl. Acad. Sci. USA, 92, 8522, 1995.
259. Bramson, J. L., Hitt, M., Addison, C. L., Muller, W. J., Gauldie, J., and Graham, F. L., Direct intratumoral injection of an adenovirus expressing interleukin-12 induces regression and long-lasting immunity that is associated with highly localized expression of interleukin-12, Hum. Gene Ther., 7, 1995, 1996.
260. Nabel, J., Nabel, E. G., Yang, Z., Fox, B. A., Plautz, G. E., Gao, X., Hung, L., Shu, S., and Gordon, D., Direct gene transfer with DNA-liposome complexes in melanoma: Expression, biologic activity, and lack of toxicity in humans, Proc. Natl. Acad. Sci. USA, 90, 11307, 1993.
261. Crystal, G., Transfer of genes to humans: Early lessons and obstacles to success, Science, 270, 404, 1995.
262. Culver, W., Ram, Z., Wallbridge, S., Ishii, H., Oldfield, E. H., and Blaese, R. M., In vivo gene transfer with retroviral vector-producer cells for treatment of experimental brain tumors, Science, 256, 1550, 1992.
263. Nemunaitis, J., Fong, T. C., Robbins, J., Edelman, G., Edwards, W., Paulson, R. S., Brute, J., Ognoskie, N., Wynne, D., Merritt, J., Jolly, D., and Ando, D., Phase I trial of γ-Interferon (IFN-γ) retroviral vector administered intratumorally to patients with metastatic melanoma, Cancer Gene Ther., 6, 322, 1999.
264. Guidance for Human Somatic Cell Therapy and Gene Therapy (www.fda.gov/cber/points.htm), March 1998.
265. Long, Z., Li, L.-P., Grooms, T., Lockey, C., Nador, K., Mychkovsky, I., Mueller, S., Burimski, I., Ryan, P., Kikuchi, G., Ennist, D., Marcus, S., Otto, E., and McGarrity, G., Biosafety monitoring of patients receiving intracerebral injections of murine retroviral vector producer cells, Hum. Gene Ther., 9, 1165, 1998.
266. Dr. Ann Pilaro, FDA presentation, meeting of the American Society for Gene Therapy, www. fda.gov/cber/summaries/asgt060999amp.ppt, June 1999.
267. Warner, J. F., Jolly D. J., and Merrit, J., Human immunodeficiency virus immunotherapy using a retroviral vector, Curr. Topics Microbiol. Immunol., 226, 145, 1998.